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During 1997–2006, general practitioner consultations 
for skin conditions for children <18 years of age in England 
increased 19%, from 128.5 to 152.9/1,000 child-years, and 
antistaphylococcal drug prescription rates increased 64%, 
from 17.8 to 29.1/1,000 child-years. During the same time 
period, hospital admissions for Staphylococcus aureus in-
fections rose 49% from 53.4 to 79.3/100,000 child-years. 
S
taphylococcus aureus infection is a leading cause of 
staphylococcal bacteremia in adults (1) and children 
(2) in hospitals in the United Kingdom, and recent reports 
suggest invasive staphylococci are emerging from the com-
munity (3). Flucloxacillin is the antimicrobial drug recom-
mended for treating S. aureus skin infection in UK primary 
care centers (4). Therefore, its use provides a proxy marker 
of S. aureus skin infection in children. Flucloxacillin pre-
scribing in children has increased over the past 15 years 
(5), despite well-documented reductions in prescribing 
rates for other commonly prescribed antibacterial drugs 
during 1995–2000 (6), which suggests that S. aureus skin 
infections in the community may be increasing.
We examined the incidence of local complications of 
S. aureus disease in children over a 10-year period using na-
tionally representative data from primary care clinicians in 
England. Ethics approval for this study was obtained from 
the Independent Scientiﬁ  c and Ethical Advisory Commit-
tee, application no. 2006/ISEAC/012.
The Study
The MediPlus UK database contains anonymized lon-
gitudinal data from >500 UK general practitioners who 
contribute clinical data on >1 million patients (7) that have 
been used widely for research (8). Consultations are coded 
by using the International Classiﬁ  cation of Diseases, Tenth 
Revision (ICD-10), and antimicrobial drug prescriptions 
are coded by using the British National Formulary for chil-
dren, Chapters 5.1.1–5.1.3 (9). Using Mediplus UK, we 
extracted data on all skin conditions (ICD-10 code) and 
atopic dermatitis (ICD-10 code L20) as an index condition 
in children <18 years of age who saw general practitioners 
in England from January 1, 1997, through December 31, 
2006. We counted prescriptions for all oral and topical an-
tibacterial drugs prescribed for skin infections, and used all 
oral preparations containing ﬂ  ucloxacillin prescribed for 
skin conditions as a proxy measure of unresolved S. au-
reus skin infection. We calculated age–sex adjusted annual 
consulting and prescribing rates by totaling the number of 
consultations or prescriptions and dividing by the number 
of person–years contributed by each child in the registered 
population for each calendar year. We then directly stan-
dardized these rates by using the age–sex distribution for 
the reference year 2000.
The Hospital Episode Statistics (HES) database has 
recorded all inpatient hospital activity in National Health 
Service hospitals across England since 1989 and is used 
widely to monitor disease trends in England (www.heson-
line.nhs.uk) (10). The main reason for admission, i.e., pri-
mary diagnosis, is recorded by using ICD-10 codes. We 
used HES data to calculate age–sex adjusted admission 
rates per 100,000 resident population for children <18 years 
of age for each calendar year from January 1, 1997, through 
December 31, 2006, for conditions commonly caused by S. 
aureus, including septic arthritis (ICD-10 codes M00.0 for 
staphylococcal arthritis and M00.9 for pyogenic arthritis), 
osteomyelitis (M86), and locally invasive skin infections 
(L02, cutaneous abscesses and boils; L03, cellulitis). Rates 
were calculated as the total number of admissions per year 
divided by the mid-year estimate of the number of children 
residing in England (using the 2000 population in England 
as the reference population) (11). Conﬁ  dence  intervals 
(CIs) were generated with a Poisson approximation. We 
used linear regression to test for linear trends in age–sex 
adjusted admission rates across the period. We used Stata 
version 9 software (Stata Corp., College Park, TX, USA) 
for all statistical analysis. 
The Mediplus database contained 2,821,372 child-
years of follow-up during 1997–2006. General practitioner 
consultation rates for all skin conditions in children rose 
from 128.5 (95% CI 127.2– 129.8) per 1,000 child-years 
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to 152.9 (95% CI 151.4–154.5) per 1,000 child years (p = 
0.011). Atopic eczema consultation rates decreased during 
this time (Figure 1).
In parallel with the rising number of skin consulta-
tions was a 64% increase in prescribing rates for anti-
staphylococcal drugs (ﬂ  ucloxacillin), from 17.8 (95% CI 
17.3–18.3) to 29.1 (95% CI 28.5–29.8) prescriptions per 
1,000 child-years (p<0.001) (Figure 2). Prescribing of 
all other antibacterial drugs for children for any reason 
decreased from 541.4 (95% CI 538.8–544.1) per 1,000 
child-years to 484.3 (95% CI 481.6–487.0) per 1,000 
child-years (Table 1). Flucloxacillin was the most com-
monly prescribed antibacterial drug for all skin conditions 
(37%). Prescribing rates for other classes of anti-bacterial 
drugs used for skin infections, notably, combined prepa-
rations of amoxicillin and clavulanic acid 2% and fusidic 
acid (<2%), were stable over the time period (Figure 2).
During 1997–2006, unplanned hospital admission rates 
for skin, bone, and joint infections in all children increased 
by 49% from 53.4 (95% CI 52.1–54.7) to 79.3 (95% CI 
77.7–80.9) per 100,000 child-years (p<0.001) including cel-
lulitis (67.8% increase; p<0.001), skin abscesses (36.7% in-
crease; p <0.001), and osteomyelitis (46.1% increase; p = 
0.004) (Table 2). This trend was consistent across all age 
groups. Admission rates for septic arthritis increased but the 
result of the test for trend was not signiﬁ  cant (p = 0.128).
Conclusions
The increasing incidence of childhood skin infections 
and prescribing of the major antistaphylococcal drug ﬂ  u-
cloxacillin seen in UK primary care, coupled with concur-
rent increases in childhood hospital admissions for skin 
bone and joint infections caused by S. aureus in hospitals 
in England, suggests an increase in community-onset S. au-
reus disease in England over the past 10 years. The time 
frame, a large nationally representative population, use of 
prospectively collected data, and consistency of patterns 
make it unlikely our ﬁ  ndings arose by chance. Because HES 
data records primary diagnosis when patients are admitted, 
most infections will be community-, not hospital-, acquired. 
Flucloxacillin has remained the treatment of choice for S. 
aureus skin infections in UK primary care for decades (9), 
and its increased use is not explained by treatment drift from 
other groups of antibacterial drugs used to treat skin infec-
tions or by increasing antibacterial drug treatment of atopic 
eczema colonized with staphylococci. Total unplanned ad-
mission rates in children <19 years of age have increased by 
13% during 1997–2006 (12), but these increases are modest 
compared with the 49% increase in S. aureus complications 
seen over the same time frame in our study.
Limitations of our study include the use of clinically 
coded proxy measures for S. aureus infections that are sub-
ject to recording bias. Because of the lack of microbiologic 
surveillance, we could not differentiate whether increases 
in S. aureus disease were caused by methicillin-sensitive 
S. aureus or methicillin-resistant S. aureus. Antimicrobial 
drugs for skin infections are available only by prescrip-
tion in the UK but not exclusively from GPs. Thus, our 
prescribing data excluded prescriptions issued from other 
healthcare settings. Our ﬁ  ndings that admission rates for 
osteomyelitis, boils, and cellulitis increased but septic ar-
thritis rates were stable might be because septic arthritis is 
also caused by pneumococci, β-hemolytic streptococci, and 
gram negative organisms (13).
A growing body of evidence supports our ﬁ  ndings of 
increases in community-onset S. aureus disease in children. 
Hospitalizations for S. aureus disease in all age groups are 
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Figure 1. General practitioner consultation and prescribing rates 
for all skin conditions in children <18 years of age, England, 1997–
2006.
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Figure 2. Prescribing rates for antibacterial drugs for children <18 
years of age, England, 1997–2006.increasing; in several countries severe skin infections, par-
ticularly among children, are rising, caused by strains of S. 
aureus producing the Panton-Valentine leukocidin (14,15). 
Although currently no formal surveillance of this strain in 
the UK is available, referrals of isolates of S. aureus posi-
tive for Panton-Valentine leukocidin to the national Staph-
ylococcal Reference Unit increased each year from 224 in 
2005 to 1,361 2007. What is not known is whether S. au-
reus community-acquired infections in children have added 
to the recently reported increases of S. aureus infection and 
bacteremias acquired in hospital settings (4). Further work 
is required to monitor S. aureus disease and antimicrobial 
drug resistance and to identify community risk factors for 
S. aureus disease in children. 
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Table 1. Age- and sex-adjusted skin condition consultation and antibacterial drug prescribing rates for children <18 years of age,
England, 1997–2006 *
Rate/1,000 child-years† (95% CI) 
Year 
GP consultations for 
skin conditions 
Antibacterial drugs for 
skin conditions 
Flucloxacillin for skin 
conditions All flucloxacillin  All antibacterial drugs 
1997 128.52
(127.21–129.83) 
59.53
(58.63–60.43) 
17.76
(17.28–18.25) 
35.04
(34.36–35.72) 
541.42
(538.75–544.09) 
1998 128.17
(126.87–129.47) 
60.44
(59.54–61.34) 
19.33
(18.83–19.84) 
37.35
(36.65–38.05) 
498.64
(496.09–501.20) 
1999 135.91
(134.57–137.24) 
65.68
(64.74–66.61) 
24.39
(23.83–24.96) 
44.03
(43.27–44.79) 
438.24
(435.84–440.63) 
2000 142.80
(141.44–144.17) 
70.17
(69.21–71.13) 
27.46
(26.86–28.06) 
48.89
(48.09–49.69) 
431.80
(429.42–434.18) 
2001 146.75
(145.36–148.14) 
73.43
(72.45–74.41) 
30.65
(30.01–31.28) 
52.76
(51.93–53.60) 
460.68
(458.21–463.14) 
2002 145.56
(144.17–146.94) 
71.64
(70.68–72.61) 
28.70
(28.09–29.32) 
51.39
(50.56–52.21) 
443.77
(441.34–446.19) 
2003 154.81
(153.37–156.24) 
75.69
(74.69–76.68) 
31.39
(30.74–32.04) 
56.00
(55.13–56.87) 
459.94
(457.45–462.43) 
2004 157.56
(156.07–159.05) 
77.51
(76.47–78.55) 
30.75
(30.09–31.42) 
56.22
(55.32–57.12) 
458.60
(456.04–461.16) 
2005 156.05
(154.54–157.57) 
75.98
(74.93–77.04) 
27.32
(26.68–27.96) 
53.58
(52.68–54.47) 
489.24
(486.55–491.93) 
2006 152.94
(151.44–154.45) 
77.62
(76.54–78.69) 
29.13
(28.47–29.80) 
56.07
(55.15–56.99) 
484.30
(481.61–486.98) 
p value‡ 0.011 0.005 0.001 0.001 0.005
*Data from International Marketing Systems Health. CI, confidence interval; GP, general practitioner. 
†Directly age-sex adjusted to 2000 sample population.  
‡p value test for linear trend across years. 
Table 2 Age- and sex-adjusted hospital admission rates for skin, bone, and joint infections in children <18 years of age, England,
1997–2006*
Rate/100,000 child-years (95% CI) 
Year 
All skin, bone, and joint 
infections
Cutaneous abscesses 
and boils Cellulitis Osteomyelitis Septic  arthritis
1997 53.38 (52.07–54.70)  25.19 (24.29–26.10)  19.81 (19.01–20.61)  4.81 (4.42–5.21)  3.57 (3.23–3.91) 
1998 57.99 (56.62–59.36)  27.37 (26.43–28.32)  22.24 (21.39–23.09)  4.82 (4.43–5.22)  3.55 (3.21–3.89) 
1999 61.34 (59.93–62.75)  28.86 (27.89–29.82)  23.63 (22.75–24.50)  5.24 (4.82–5.65)  3.62 (3.28–3.96) 
2000 64.95 (63.49–66.41)  28.94 (27.97–29.91)  26.48 (25.55–27.41)  5.70 (5.27–6.14)  3.83 (3.47–4.18) 
2001 61.99 (60.56–63.41)  28.02 (27.06–28.98)  25.25 (24.34–26.16)  5.55 (5.12–5.97)  3.17 (2.85–3.50) 
2002 63.65 (62.20–65.09)  29.65 (28.66–30.64)  25.01 (24.11–25.92)  5.45 (5.02–5.87)  3.54 (3.19–3.88) 
2003 71.15 (69.62–72.68)  32.71 (31.68–33.75)  29.26 (28.27–30.24)  5.39 (4.97–5.81)  3.79 (3.43–4.14) 
2004 73.66 (72.11–75.22)  32.98 (31.94–34.02)  30.63 (29.63–31.64)  6.11 (5.66–6.56)  3.94 (3.58–4.30) 
2005 76.26 (74.67–77.84)  35.17 (34.10–36.25)  32.03 (31.00–33.05)  5.63 (5.20–6.07)  3.43 (3.09–3.76) 
2006 79.28 (77.66–80.89)  34.43 (33.37–35.49)  33.23 (32.18–34.28)  7.04 (6.55–7.52)  4.58 (4.19–4.97) 
p value†  <0.001 <0.001 <0.001 0.004 0.128
*Data from Hospital Episode Statistics. Rates directly adjusted to mid-year 2000 resident population for England. International Classification of Diseases, 
Tenth Revision, codes for primary diagnosis at admission: cutaneous abscesses and boils, L02; cellulitis, L03; osteomyelitis, M86; septic arthritis 
(staphylococcal arthritis, M00.0, or pyogenic arthritis, M00.9). All of these codes were included in the category “all skin, bone, and joint infections.” CI, 
confidence interval. 
†p value for test for linear trend across years. S. aureus Complications in Children, England
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